TY - JOUR
T1 - Subjective Cognitive Impairment Cohort (SCIENCe)
T2 - study design and first results
AU - Slot, Rosalinde E R
AU - Verfaillie, Sander C J
AU - Overbeek, Jozefien M
AU - Timmers, Tessa
AU - Wesselman, Linda M P
AU - Teunissen, Charlotte E
AU - Dols, Annemiek
AU - Bouwman, Femke H
AU - Prins, Niels D
AU - Barkhof, Frederik
AU - Lammertsma, Adriaan A
AU - Van Berckel, Bart N M
AU - Scheltens, Philip
AU - Sikkes, Sietske A M
AU - Van der Flier, Wiesje M
PY - 2018/8/7
Y1 - 2018/8/7
N2 - BACKGROUND: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.METHODS: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression.RESULTS: Cross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer's disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7-38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6-15.0)) were associated with preclinical AD.CONCLUSIONS: The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.
AB - BACKGROUND: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.METHODS: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression.RESULTS: Cross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer's disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7-38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6-15.0)) were associated with preclinical AD.CONCLUSIONS: The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.
U2 - https://doi.org/10.1186/s13195-018-0390-y
DO - https://doi.org/10.1186/s13195-018-0390-y
M3 - Article
C2 - 30081935
SN - 1758-9193
VL - 10
JO - Alzheimer's Research & Therapy
JF - Alzheimer's Research & Therapy
M1 - 76
ER -